(24/7 MARKET NEWS) – PolyPid Ltd. (Nasdaq: PYPD) provided a positive regulatory update, this morning, for D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs), following a recent type D meeting communication with the FDA on the SHIELD I Phase 3 data, the Company now has clarity regarding the regulatory pathway toward a potential New Drug Application (NDA) submission.
PolyPid is trading at $1.17, up $0.19, on volume of 100 thousand shares traded.
Its 52-week range is $0.65 to $6.90. We don’t like most foreign based listings, but this one has a very interesting chart, as it doesn’t appear to have much resistance to the $2 level and then it has a gap to the $5 level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.